Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Screening of therapeutic strategies for Huntington's disease in YAC128 transgenic mice.

Gil-Mohapel JM.

CNS Neurosci Ther. 2012 Jan;18(1):77-86. doi: 10.1111/j.1755-5949.2011.00246.x. Review.

PMID:
21501423
2.

Mechanisms of neurodegeneration in Huntington's disease.

Gil JM, Rego AC.

Eur J Neurosci. 2008 Jun;27(11):2803-20. doi: 10.1111/j.1460-9568.2008.06310.x. Review. Erratum in: Eur J Neurosci. 2008 Nov;28(10):2156.

PMID:
18588526
3.
4.

Mouse models of Huntington's disease.

Menalled LB, Chesselet MF.

Trends Pharmacol Sci. 2002 Jan;23(1):32-9. Review.

PMID:
11804649
5.

Selective degeneration in YAC mouse models of Huntington disease.

Van Raamsdonk JM, Warby SC, Hayden MR.

Brain Res Bull. 2007 Apr 30;72(2-3):124-31. Epub 2006 Nov 16. Review.

PMID:
17352936
6.

The early cellular pathology of Huntington's disease.

Li XJ.

Mol Neurobiol. 1999 Oct-Dec;20(2-3):111-24. Review.

PMID:
10966117
7.

Transgenic animal models for study of the pathogenesis of Huntington's disease and therapy.

Chang R, Liu X, Li S, Li XJ.

Drug Des Devel Ther. 2015 Apr 15;9:2179-88. doi: 10.2147/DDDT.S58470. eCollection 2015. Review.

8.

[Huntington disease. A review].

Bonilla E.

Invest Clin. 2000 Jun;41(2):117-41. Review. Spanish.

PMID:
10961047
9.

Mutant huntingtin can paradoxically protect neurons from death.

Zuchner T, Brundin P.

Cell Death Differ. 2008 Mar;15(3):435-42. Epub 2007 Nov 2. Review.

10.

Huntington disease: new insights on the role of huntingtin cleavage.

Wellington CL, Leavitt BR, Hayden MR.

J Neural Transm Suppl. 2000;(58):1-17. Review.

PMID:
11128600
11.

The R6 lines of transgenic mice: a model for screening new therapies for Huntington's disease.

Gil JM, Rego AC.

Brain Res Rev. 2009 Mar;59(2):410-31. doi: 10.1016/j.brainresrev.2008.12.001. Epub 2008 Dec 16. Review.

PMID:
19118572
12.

Hypothalamic and neuroendocrine changes in Huntington's disease.

Hult S, Schultz K, Soylu R, Petersén A.

Curr Drug Targets. 2010 Oct;11(10):1237-49. Review.

PMID:
20594177
13.

[Huntington's disease: clinical and molecular genetics].

Warita H, Shiro Y, Kashihara K, Abe K.

Nihon Rinsho. 1999 Apr;57(4):896-9. Review. Japanese.

PMID:
10222786
14.

Experimental models of HD and reflection on therapeutic strategies.

Kim J, Bordiuk OL, Ferrante RJ.

Int Rev Neurobiol. 2011;98:419-81. doi: 10.1016/B978-0-12-381328-2.00016-X. Review.

PMID:
21907096
15.

Mouse models of Huntington's disease and methodological considerations for therapeutic trials.

Ferrante RJ.

Biochim Biophys Acta. 2009 Jun;1792(6):506-20. doi: 10.1016/j.bbadis.2009.04.001. Epub 2009 Apr 10. Review.

16.

The use of transgenic and knock-in mice to study Huntington's disease.

Hickey MA, Chesselet MF.

Cytogenet Genome Res. 2003;100(1-4):276-86. Review.

PMID:
14526189
17.

Transgenic models of Huntington's disease.

Sathasivam K, Hobbs C, Mangiarini L, Mahal A, Turmaine M, Doherty P, Davies SW, Bates GP.

Philos Trans R Soc Lond B Biol Sci. 1999 Jun 29;354(1386):963-9. Review.

18.

The therapeutic potential of G-protein coupled receptors in Huntington's disease.

Dowie MJ, Scotter EL, Molinari E, Glass M.

Pharmacol Ther. 2010 Nov;128(2):305-23. doi: 10.1016/j.pharmthera.2010.07.008. Epub 2010 Aug 11. Review.

PMID:
20708032
19.

Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease.

Nithianantharajah J, Hannan AJ.

Neuroscience. 2013 Oct 22;251:66-74. doi: 10.1016/j.neuroscience.2012.05.043. Epub 2012 May 24. Review.

PMID:
22633949
20.

Molecular aspects of Huntington's disease.

Walling HW, Baldassare JJ, Westfall TC.

J Neurosci Res. 1998 Nov 1;54(3):301-8. Review.

PMID:
9819135

Supplemental Content

Support Center